Prime Medicine's new CEO Allan Reine walks us through the prime editing company's new focused pipeline

He describes the benefits of prime editing, walks us through human proof-of-concept data that was announced in a patient with Chronic Granulomatous Disease, and explains the rationale to focus on Wilson's Disease, Alpha-1 Antitrypsin Deficiency, Cystic Fibrosis, and the company's CAR-T partnership with Bristol Myers Squibb.